On January 21, 2016, Cure First brought together prominent experts from a variety of disciplines—clinical oncology, computational sciences, patient advocacy, pharmaceutical R&D, cancer research, and genetics—to share their work and vision about the realities and possibilities of new cancer therapies.
MED Talk Presentations
Cancer Think Tank provided a forum for experts to consider the potential of applying the latest advances in functional genomics, cutting-edge robotic technology and high-throughput screening (HTS) to identify the possibilities of personalized medicine and to further our understanding of how to kill cancer.
Platforms and insights into potentially groundbreaking science and technology were shared through MED Talk presentations. Then, working with small groups, facilitators helped harness ideas and examples of what could be done to develop new approaches for treating cancer. Research themes that surfaced from group interactions were shared with the larger group for further investigation. The facilitators are currently working to identify topics for potential grants and will be contacting Cancer Think Tank participants to review these ideas and to solicit their collaboration in developing them into grants.
Funding for specific initiatives emerging from the conference will be pursued in the coming months. Participants interested in working with other specialists will be invited to write segments of grant applications using a structured approach to encourage faster development. Strategic submissions to funding institutions such as the NIH and NCI will follow.
- FEBRUARY: Consolidate ideas and create teams.
- MARCH—MAY: Gather ideas, draft proposals and investigate possible funding sources.
- JUNE—FALL: Submit applications according to specific deadlines.
- Winter 2016/17: BEGIN RESEARCH
BOB EISENMAM: "Oncogenesis: It Takes a Network"—What does it take to find the personalized cure for cancer?
ILYA SHMULEVICH: "The Engineering Approach to Cancer"—How can analytical tools traditionally used in engineering, such as systems modeling and simulation, be applied to the problems of developing personalized therapies for cancer?
JERRY RADICH: "The Genetics of Luck"—Some patients who should do great, don’t. Others shouldn’t do well, but do great. This is often ascribed to luck. Is it, or is there something more?
RAVI PANDYA: "Computational Medicine for Cancer"—Sophisticated software algorithms and large scale cloud computing systems are becoming essential to understanding and treating the complex and diverse genomic alterations that cause cancer.
VK GADI: "Breakthroughs in Fighting Breast Cancer"—Building functional genomics maps to deliver better treatments.